Trial NCT05049226
Publication Niyomnaitham S, medRxiv, 2022
Primary outcome on the report: 1) IgG levels against Anti-S RBD, at baseline, 28, 60 and 90 days after the third-dose/booster; 2) functional (neutralizing) humoral immune response, elicited by each regimen was also assessed by the PNA at baseline, 28, and 90 days post-third dose; 3) Third-dose vaccination safety and tolerability were evaluated at different intervals.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.